Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- PRCT +14.2%
Other news:
- EVOK +134.5% (Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI)
- GLUE +37.6% (announces a global exclusive development and commercialization license agreement with Novartis (NVS) to advance VAV1 MGDs, including MRT-6160)
- LENZ +11% (LENZ Therapeutics and CORXEL announce topline data from China Phase 3 Presbyopia Trial of LNZ100)
- IRWD +10.6% (will present new findings at the American College of Gastroenterology 2024 Annual Scientific Meeting and Postgraduate Course from subgroup analyses of the primary endpoint of the pivotal Phase III clinical trial)
- VERA +10.1% (Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024)
- BCLI +9.2% (Presented Positive Survival Data from NurOwn Expanded Access Program at 2024 Annual NEALS Meeting)
- AZUL +7.5% (obtains additional funding and crystalizes Lessor/OEM agreements)
- ESLT +6.4% (receives $200 mln contract by the Israeli MOD to supply high-power laser for the "Iron Beam" Air Defense System)
- RUN +5.3% (in discussions to sell solar to data centers, according to Bloomberg)
- EYPT +5.3% (Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU for Diabetic Macular Edema)
- HE +5% (Kenneth Griffin of Citadel Advisors discloses 5.4% stake)
- APLS +4% (Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN)
- CLDX +3.9% (Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria)
- NCLH +3.7% (rising on lower oil prices)
- CCL +3.2% (rising on lower oil prices)
- RCL +2.2% (rising on lower oil prices)
- PLL +1.9% (reports Q3 operating results)
- TVTX +1.5% (Presents Data Reinforcing Clinical Benefit of FILSPARI (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024)
- LGO +1.4% (Announces Results of an Updated Life of Mine Plan and Pre-Feasibility Study for its Vanadium-Titanium Operation in Brazil: 67% Increase in Mineral Reserves, 64% Increase in Mineral Resources, 31-Year Mine Life with US$1.1 Billion NPV7% Estimate)
- TYRA +1.4% (receives IND clearance from FDA to proceed with Phase 2 Study of TYRA-300)